• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by OnKure Therapeutics Inc.

    12/9/24 4:30:51 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OKUR alert in real time by email
    S-8 1 okur_s-8_20241209_no_xbr.htm S-8 S-8

    As filed with the Securities and Exchange Commission on December 9, 2024

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    ONKURE THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    47-2309515

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    6707 Winchester Circle, Suite 400
    Boulder, Colorado 80301

    (Address of Principal Executive Offices, including zip code)

     

    OnKure Therapeutics, Inc. 2024 Equity Incentive Plan
    OnKure Therapeutics, Inc. 2024 Employee Stock Purchase Plan

    OnKure, Inc. 2011 Stock Incentive Plan

    OnKure, Inc. 2021 Stock Incentive Plan

    OnKure, Inc. 2023 RSU Equity Incentive Plan

    (Full title of the plan)

    Nicholas A. Saccomano
    President and Chief Executive Officer
    6707 Winchester Circle, Suite 400

    Boulder, CO 80301

    (720) 307-2892

    (Name, address and telephone number, including area code, of agent for service)

    Copies to:

    Tony Jeffries

    Jennifer Knapp

    Phillip McGill

    Wilson Sonsini Goodrich & Rosati, P.C.

    1155 Canyon Blvd., Suite 400

    Boulder, CO 80302

    (303) 256-5900

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is filed by OnKure Therapeutics, Inc. (the “Registrant”) for the purpose of registering an aggregate of 3,959,930 shares of the Registrant’s Class A common stock, par value $0.0001 per share (“Class A Common Stock”), consisting of (i) 1,673,179 shares issuable under the Company’s 2024 Equity Incentive Plan (the “2024 Plan”), representing 737,338 shares of Class A Common Stock reserved for issuance under the 2024 Plan as of the date of this Registration Statement, and up to an additional 935,841 shares of Class A Common Stock that may become issuable under the 2024 Plan pursuant to its terms as a result of the forfeiture or termination of awards under the prior Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan or the forfeiture or termination of awards assumed by OnKure Therapeutics, Inc. that were granted under the prior OnKure, Inc. 2011 Stock Incentive Plan (the “2011 Plan”), the prior OnKure, Inc. 2021 Stock Incentive Plan (the “2021 Plan"), and/or the prior OnKure, Inc. 2023 RSU Equity Incentive Plan (the “2023 Plan”), (ii) 1,742,662 shares of Class A Common Stock which are subject to currently outstanding stock options under the 2024 Plan, (iii) 137,500 shares of Class A Common Stock reserved for issuance under the Company’s 2024 Employee Stock Purchase Plan, (iv) 221 shares of Class A Common Stock which are subject to currently outstanding stock options under the 2011 Plan, (v) 193,114 shares of Class A Common Stock which are subject to currently outstanding stock options under the 2021 Plan, and (vi) 213,254 restricted stock units covering shares of Class A Common Stock currently outstanding under the 2023 Plan.

     

    PART I

    INFORMATION REQUIRED IN THE PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the “SEC”):

    1.
    The Registrant’s Annual Report on Form 10-K (File No. 001-40315) for the fiscal year ended December 31, 2023 filed with the SEC on March 28, 2024, as amended on April 26, 2024;
    2.
    The Registrant’s Quarterly Report on Form 10-Q (File No. 001-40315) for the quarterly period ended March 31, 2024 filed with the SEC on May 7, 2024;
    3.
    The Registrant’s Quarterly Report on Form 10-Q (File No. 001-40315) for the quarterly period ended June 30, 2024 filed with the SEC on August 13, 2024;
    4.
    The Registrant’s Quarterly Report on Form 10-Q (File No. 001-40315) for the quarterly period ended September 30, 2024, filed with the SEC on November 7, 2024;
    5.
    The Registrant’s Final Prospectus filed with the SEC on October 31, 2024 pursuant to Rule 424(b) under the Securities Act relating to the Registration Statement on Form S-1 (File No. 333-282792), which contains the Registrant’s audited financial statements for the latest fiscal year for which such statements have been filed;

     

     


    6.
    The Registrant’s Current Reports on Form 8-K filed on February 23, 2024, May 13, 2024, September 13, 2024, September 20, 2024, October 2, 2024, October 8, 2024, and November 7, 2024 (other than information furnished rather than filed);
    7.
    All other reports filed with the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (1) above, only to the extent that the items therein are specifically stated to be “filed” rather than “furnished” for the purposes of the Exchange Act; and
    8.
    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the SEC on April 6, 2021 pursuant to Section 12(b) of the Exchange Act, and as set forth in the description of the Registrant’s securities set forth in the Registrant’s Final Prospectus filed with the SEC on October 31, 2024, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law (the “DGCL”) authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

    We have adopted provisions in our charter that eliminate or limit the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be

     

     


    amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

    •
    any breach of the director’s duty of loyalty to us or our stockholders;
    •
    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
    •
    any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
    •
    any transaction from which the director derived an improper personal benefit.

    These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

    In addition, our bylaws provide that:

    •
    We will indemnify our directors, officers, and in the discretion of our board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and
    •
    We will advance expenses, including attorneys’ fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions.

    We have entered into separate indemnification agreements with our directors and officers that may be broader than the specific indemnification provisions contained in the DGCL. We have entered into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our certificate of incorporation. Our bylaws also permit us to maintain insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such indemnification. We have obtained a policy of director’s and officer’s liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of directors and officers for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The Registrant has filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement.

     

     

     


     

     

    EXHIBIT INDEX

    Exhibit
    Number

    Exhibit Description

    Incorporated by Reference

     

     

    Form

    File No.

    Exhibit

    Filing Date

    4.1

    Amended and Restated Certificate of Incorporation, as amended, of OnKure Therapeutics, Inc.

    8-K

    001-40315

    3.2

    October 8, 2024

    4.2

    Amended and Restated Bylaws of OnKure Therapeutics, Inc.

    8-K

    001-40315

    3.3

    October 8, 2024

    4.3

    Specimen Common Stock Certificate.

    S-1

    333-254534

    4.1

    April 5, 2021

    4.4

    2024 Equity Incentive Plan and forms of agreement thereunder.

    8-K

    001-40315

    10.14

    October 8, 2024

    4.5

    2024 Employee Stock Purchase Plan

    8-K

    001-40315

    10.15

    October 8, 2024

    4.6

    OnKure, Inc. 2011 Stock Incentive Plan, as amended, and forms of agreement thereunder.

    8-K

    001-40315

    10.16

    October 8, 2024

    4.7

    OnKure, Inc. 2021 Stock Incentive Plan, as amended, and forms of agreement thereunder.

    8-K

    001-40315

    10.17

    October 8, 2024

    4.8

    OnKure, Inc. 2023 RSU Equity Incentive Plan, and forms of agreement thereunder.

    8-K

    001-40315

    10.18

    October 8, 2024

    5.1

    Opinion of Wilson Sonsini Goodrich & Rosati, P.C.

    23.1

    Consent of Ernst & Young LLP, independent registered public accounting firm.

    23.2

    Consent of KPMG LLP, independent registered public accounting firm.

    23.3

    Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto).

     

     

     

     

    24.1

    Power of Attorney (included on the signature page hereto).

    107

    Filing Fee Table

    Item 9. Undertakings.

    A. The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective Registration Statement;

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the

     

     


    Registration Statement; provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    C. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on December 9, 2024.

    ONKURE THERAPEUTICS, INC.

     

     

    By:

    /s/ Nicholas A. Saccomano

     

    Nicholas A. Saccomano

     

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Nicholas A. Saccomano and Jason Leverone, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments) on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact, proxy and agent, or any substitute of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

    Signature

    Title

    Date

     

     

     

    /s/ Nicholas A. Saccomano

    Nicholas A. Saccomano

    Chief Executive Officer, President and Director

    (Principal Executive Officer)

    December 9, 2024

     

     

     

    /s/ Jason Leverone

    Jason Leverone

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    December 9, 2024

     

     

     

    /s/ R. Michael Carruthers

    R. Michael Carruthers

    Director

    December 9, 2024

     

     

     

    /s/ Michael Grey

    Michael Grey

    Director

    December 9, 2024

     

     

     

    /s/ Valerie M. Jansen

    Valerie M. Jansen

    Director

    December 9, 2024

     

     

     

    /s/ Isaac Manke

    Isaac Manke

    Director

    December 9, 2024

     

     

     

     

    /s/ Edward T. Mathers

    Director

    December 9, 2024

    Edward T. Mathers

     

     

     

     

     

    /s/ Andrew Phillips

    Chairman

    December 9, 2024

    Andrew Phillips

     

     

     

     

     


     

     

     


    Get the next $OKUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OKUR

    DatePrice TargetRatingAnalyst
    4/30/2025Outperform
    Evercore ISI
    12/5/2024$33.00Outperform
    Leerink Partners
    10/10/2024$35.00Outperform
    Oppenheimer
    More analyst ratings

    $OKUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

    -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next-generation PI3Kα pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 -- Expansion into Vascular Malformations - additional information to be provid

    11/6/25 4:03:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure Therapeutics to Participate in Upcoming Investor Conferences

    BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Guggenheim Healthcare Innovation Conference, in Boston on Monday, November 10, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this link. A corporate presentation at the Stifel Healthcare Conference, in New York on November 12, 2025, at 4:00 p.m. ET. A live audio webcast

    11/4/25 4:05:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

    -- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with fulvestrant and ribociclib in HR+ metastatic breast cancer -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with trastuzumab and tucatinib in HER2+ metastatic breast cancer -- Cash position of $83.4M expected to provide cash runway into Q4 2026 BOULDER, Colo., Aug. 12, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutic

    8/12/25 4:05:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by OnKure Therapeutics Inc.

    SCHEDULE 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    1/30/26 2:21:49 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.

    SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/28/25 8:15:23 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by OnKure Therapeutics Inc.

    424B3 - OnKure Therapeutics, Inc. (0001637715) (Filer)

    11/21/25 4:09:22 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on OnKure Therapeutics

    Evercore ISI initiated coverage of OnKure Therapeutics with a rating of Outperform

    4/30/25 8:12:14 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on OnKure Therapeutics with a new price target

    Leerink Partners initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $33.00

    12/5/24 8:06:23 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on OnKure Therapeutics with a new price target

    Oppenheimer initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $35.00

    10/10/24 7:48:05 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Acorn Bioventures, L.P. bought $2,590,000 worth of shares (1,400,000 units at $1.85) (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    5/19/25 4:43:34 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mathers Edward T was granted 3,911 shares, increasing direct ownership by 34% to 15,310 units (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    1/2/26 4:16:56 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manke Isaac was granted 5,258 shares, increasing direct ownership by 34% to 20,583 units (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    1/2/26 4:10:23 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Saccomano Nicholas A sold $258 worth of shares (87 units at $2.97), decreasing direct ownership by 1% to 7,419 units (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    12/23/25 8:09:47 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Leadership Updates

    Live Leadership Updates

    View All

    OnKure Announces New Date for Upcoming Investor Call

    BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10th. OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. E

    11/25/24 5:31:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Financials

    Live finance-specific insights

    View All

    OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

    -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025 -- Management to host conference call today, December 10, 2024 at 7:00 a.m. CT BOULDER, Colo., Dec. 10, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medi

    12/10/24 7:00:00 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

    OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D

    11/1/24 5:30:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

    SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/14/24 4:00:05 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OnKure Therapeutics Inc.

    SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/14/24 10:11:45 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

    SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    10/28/24 4:03:06 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care